Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

详细信息    查看全文

• 作者：Mary D. Ruppe^a ; ^{mdruppe@houstonmethodist.org} ; Xiaoping Zhang^b ; Erik A. Imel^c ; Thomas J. Weber^d ; Mark A. Klausner^b ; Takahiro Ito^b ; Maria Vergeire^b ; Jeffrey S. Humphrey^b ; Francis H. Glorieux^e ; Anthony A. Portale^f ; Karl Insogna^g ; Munro Peacock^c ; Thomas O. Carpenter^g
• 关键词：PRO ; patient reported outcomes ; HRQoL ; health-related quality of life ; WOMAC ; Western Ontario and McMaster Osteoarthritis Index ; MIC ; Minimally Important Change
• 刊名：Bone Reports
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：5
• 期：Complete
• 页码：158-162
• 全文大小：426 K
• 卷排序：5

文摘

Quality of life was assessed in 26 XLH patients before and after 4 months of treatment with KRN23. All mean scores showed a trend of improved health after 4 doses of KRN23 treatment. Role limitations due to physical health was significantly improved after multiplicity correction. Patient reported outcomes can provide valuable information in evaluating new treatments for XLH.